This Week in Cardiology

Discover the surprising cardiac risks of endurance athletes revealed in the VENTOUX study, highlighting potential heart issues tied to intense training. Uncover the truth behind the 10,000-step myth, as new research suggests even 7,000 steps can boost health. Delve into the debate over rate versus rhythm control for atrial fibrillation and learn about the impact of GLP-1 drugs in observational studies, linking them to neurodegeneration and stroke. It's a deep dive into the complexities of heart health!

Discover the latest on finerenone's FDA approval for heart failure and the complexities of choosing between TAVI and surgical AVR for aortic stenosis. Dive into the risks of catheter ablation, including brain lesions and visual migraines, as revealed by the TRAVERSE trial. The discussion also evaluates the impacts of atrial fibrillation treatments on brain health. With critiques of recent studies and a hopeful look at healthcare policy reforms, there's a wealth of engaging insights for healthcare professionals.

Dive into the world of cardiology controversies, including the heated debate over ticagrelor's efficacy and safety in trials. Discover insights on the longevity of ICD batteries and what it means for patient care. The PRAGUE-25 trial is highlighted as a pivotal study this year, stimulating discussions on the future of electrophysiology as a profession. The episode also features personal anecdotes blending professional insights with lighthearted moments from recent celebrations.

Discover groundbreaking news as the FDA approves a triple-drug polypill for hypertension, igniting discussions on its pros and cons. Explore evolving views on managing hypertension, especially in elderly patients. Dive into innovative invasive therapies for pulmonary embolism, revealing both techniques and knowledge gaps. Heart disease trends and the increasing urgency of diabetes care are also highlighted, showcasing the latest in cardiology. Tune in for expert insights and a blend of humor on these vital health topics!

Delve into the cutting-edge world of cardiac imaging with a focus on coronary CT angiography. Discover how CTA influences patient management and risk assessment. Insights from the Scott Heart trials reveal surprising relationships between symptoms and coronary plaque. Furthermore, a critical evaluation of the new EVOQUE valve raises important questions about its real-world effectiveness. Join the discussion on how these advancements reshape cardiology.

Listeners weigh in on cardiac sarcoidosis and the use of imaging for risk assessment. The podcast tackles the complexities of sinus node ablation and the need for careful treatment approaches. It also dives into the challenges faced in recruiting patients for critical cardiovascular trials, shedding light on the implications for study outcomes and evidence validity. Additionally, there's a discussion on surgical atrial fibrillation ablation during CABG, highlighting the need for more robust research.

Listener feedback shines light on cardiac sarcoidosis and emerging awareness of bystander CPR. Experts discuss the phrase 'less is more' in post-stent antiplatelet therapy for better outcomes. Lipoprotein(a) is explored as a significant factor in cardiovascular risk. The complexities of managing atrial fibrillation in patients with heart failure are dissected, emphasizing the need for collaboration with specialists. Engaging insights prompt healthcare professionals to rethink patient care strategies.

Listener feedback, CRT vs CSP, important clues on the ECG, beta-blocker interruption after myocardial infarction, novel approaches to LDL-C lowering, and ICD decisions in cardiac sarcoidosis are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback II CRT vs CSP – CONSYST-CRT • Trial JACC EP https://doi.org/10.1016/j.jacep.2025.03.024 III The Important QRS • Kewcharoen et al https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013809 IV ABYSS Trial of BB Interruption after MI Continues to be Mis-interpreted • ABYSS Main https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 • ABYSS substudy https://doi.org/10.1093/eurheartj/ehaf170 • REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479 V Oral PCSK9i and the PURSUIT Trial • Koren et al https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499 • Editorial https://doi.org/10.1016/j.jacc.2025.03.518 • Is Lifelong LDL-C Lowering Within Reach? The heart-1 Gene-Editing Trial https://www.medscape.com/viewarticle/998162 • Heart-1 Gene Therapy Trial Pauses Enrollment https://www.medscape.com/viewarticle/998162 • EHJ coverage VERVE https://academic.oup.com/ehjcvp/article/10/2/87/7455877 VI Cardiac Sarcoidosis and Risk of VT • EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback kicks off discussions about sports disqualification linked to genetic heart disease. Exciting updates on digoxin's role in heart failure and the implications of Brugada syndrome add depth. The show dives into innovative treatments like finerenone, weighing its efficacy against traditional options. A sharp critique of trial methodologies highlights the importance of sham controls in enhancing research validity. Overall, a blend of cutting-edge research and practical insights for healthcare professionals makes for a compelling listen!

Explore groundbreaking findings on blood pressure medication timing, revealing that when you take them may not matter as much as once thought. Discover the competitive edge of tirzepatide over semaglutide in promoting weight loss and improving cardiometabolic health. Delve into age-specific troponin reference limits, particularly relevant for older patients. Plus, learn about genetic factors in athletes and the rapid titration benefits for heart failure treatments, highlighted by recent clinical trials.